Lack of effect of incretin hormones on insulin release from pancreatic islets in the bile duct-ligated rats.
Hyperglycemia associated with obstructive jaundice seriously affects the prognosis of patients with hepatobiliary diseases. We investigated secretory properties of isolated islets from bile duct-ligated (BDL) rats. Pancreatic islets from BDL rats lost their secretory responses to glucagon-like peptide-1 (GLP-1), although their responses to glucose were normal. Loss of potentiation of insulin release was also observed in glucagon and glucose-dependent insulinotropic peptide (GIP), whereas modulation of the release by forskolin, dibutyryl cAMP, or epinephrine remained unaffected. cAMP production by BDL islets was not increased by these insulinotropic hormones. Serum levels of glucagon, but not GIP, were increased in BDL rats. GLP-1 levels were also elevated, although they did not reach statistical significance. Immunoblotting of trimeric G protein subunits demonstrated that G(s)alpha L and G(s)alpha S, but not G(i)alpha 1/2 and G(i)alpha 3/o alpha, were less expressed in BDL islets. Therefore, unresponsiveness of the beta-cell to cAMP-raising hormones is involved in glucose intolerance under cholestasis. It results from diminished expression of alpha-subunits of the relevant G protein, G(s), and desensitization of receptors of these hormones.
Niwa
T
T
Department of Cell Pharmacology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
Nimura
Y
Y
Niki
I
I
D000818:Animals; D001652:Bile Ducts / Q000601:surgery; D001663:Bilirubin / Q000494:pharmacology; D003994:Bucladesine / Q000494:pharmacology; D001651:Cholestasis, Extrahepatic / Q000378:metabolism*; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D005934:Glucagon / Q000097:blood / Q000494:pharmacology; D052216:Glucagon-Like Peptide 1; D004763:Glucagon-Like Peptides; D005947:Glucose / Q000494:pharmacology; D005951:Glucose Tolerance Test; D020962:Heterotrimeric GTP-Binding Proteins / Q000378:metabolism; D066298:In Vitro Techniques; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism*; D008026:Ligation; D008297:Male; D010446:Peptide Fragments / Q000097:blood* / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
D007328:Insulin; D010446:Peptide Fragments; C055453:glucagon-like peptide 1 (7-36)amide; D005576:Colforsin; D004763:Glucagon-Like Peptides; D003994:Bucladesine; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000242:Cyclic AMP; D020962:Heterotrimeric GTP-Binding Proteins; D005947:Glucose; D001663:Bilirubin